Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Response Genetics, Inc. (OTC: RGDXQ).

Full DD Report for RGDXQ

You must become a subscriber to view this report.



Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-140.0011050.0011050.0011050.0011058,000
2018-12-13N/A0.0011N/AN/A0
2018-12-120.0010.00110.00110.00163,500
2018-12-110.001020.0010.001020.00117,775
2018-12-10N/A0.0011N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-11-291,310,0001,310,000100.0000Short
2018-11-274,5004,500100.0000Short
2018-10-2230,00050,00060.0000Short
2018-10-1910,00018,00055.5556Short
2018-10-1810,000100,00010.0000Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on RGDXQ.


About Response Genetics, Inc. (OTC: RGDXQ)

Logo for Response Genetics, Inc. (OTC: RGDXQ)

Response develops, manufactures and markets rapid onsite diagnostic tests for use with its RAMP platform for clinical, biodefense and environmental applications. RAMP represents a unique paradigm in diagnostics that provides reliable, quality results in minutes. The RAMP platform consists of a reader and single use disposable test cartridges and has the potential to be adapted to any other medical and nonmedical immunoassay based test currently performed in laboratories. Response clinical tests are commercially available for the aid in early detection of heart attack, congestive heart failure, thromboembolism and infectious diseases. In the nonclinical market, RAMP tests are currently available for the environmental detection of West Nile Virus antigen and for Biodefense applications including the rapid onsite detection of anthrax, smallpox, ricin and botulinum toxin.

 

 

 

Current Management

  • Thomas Bolonga / CEO
    • Thomas A. Bologna joined Response Genetics as our Chief Executive Officer in December . From April until joining Response Genetics, Mr. Bologna served as President and Chief Executive Officer of Orchid Cellmark, Inc., a NASDAQlisted corporation and a leading service provider of DNA identity testing. Prior to joining Orchid Cellmark, Mr. Bologna was President, Chief Executive Officer and a member of the board of the venturebacked Quorex Pharmaceuticals, Inc., where he orchestrated a successful sale to Pfizer Inc. Prior to leading Quorex, Mr. Bologna was Chairman of the Board, President and Chief Executive Officer of Ostex International, Inc., a NASDAQlisted biotechnology company that developed and commercialized disease management products with a focus on osteoporosis. Mr. Bologna oversaw the sale of Ostex to Alere Inc. formally Inverness Medical Innovations . Mr. Bologna s prior experience includes serving as President and Chief Executive Officer of Scriptgen Pharmaceuticals, Inc., a Boston biotechnology startup company. Before leading Scriptgen, Mr. Bologna was Chairman of the Board, President and Chief Executive Officer of GenProbe, Incorporated, a global leader in the development, manufacture and marketing of molecular diagnostic products. He led GenProbe through its initial public offering on NASDAQ and oversaw its subsequent sale to Chugai Pharmaceutical Co., Ltd. Mr. Bologna has also held seniorlevel positions with Becton Dickinson amp Company and WarnerLambert Company Pfizer , two leading Fortune healthcare companies. Mr. Bologna served as President of the Becton Dickinson Diagnostic Instrument Systems Division and as a Vice President of the WarnerLambert Company.
  • Kevin R. Harris / CFO, Principal Fin. Officer
    • Mr. Harris previously served as Chief Financial Officer and a director of CyberDefender Corporation from until August and as interim Chief Executive Officer from August until August and as Chief Operating Officer of Statmon Technologies Corp from to . He began his career at KPMG Peat Marwick as a senior auditor. Mr. Harris s other professional experience includes serving as Head of Production, Finance at PolyGram Television, Director of Corporate Financial Planning at MetroGoldwynMayer Studios and Senior Vice President of Finance at RKO Pictures. Mr. Harris earned a Bachelor of Science in Business Administration from California State University, San Bernardino and is a Certified Public Accountant in the State of California.
  • Thomas Bolonga / Director
    • Thomas A. Bologna joined Response Genetics as our Chief Executive Officer in December . From April until joining Response Genetics, Mr. Bologna served as President and Chief Executive Officer of Orchid Cellmark, Inc., a NASDAQlisted corporation and a leading service provider of DNA identity testing. Prior to joining Orchid Cellmark, Mr. Bologna was President, Chief Executive Officer and a member of the board of the venturebacked Quorex Pharmaceuticals, Inc., where he orchestrated a successful sale to Pfizer Inc. Prior to leading Quorex, Mr. Bologna was Chairman of the Board, President and Chief Executive Officer of Ostex International, Inc., a NASDAQlisted biotechnology company that developed and commercialized disease management products with a focus on osteoporosis. Mr. Bologna oversaw the sale of Ostex to Alere Inc. formally Inverness Medical Innovations . Mr. Bologna s prior experience includes serving as President and Chief Executive Officer of Scriptgen Pharmaceuticals, Inc., a Boston biotechnology startup company. Before leading Scriptgen, Mr. Bologna was Chairman of the Board, President and Chief Executive Officer of GenProbe, Incorporated, a global leader in the development, manufacture and marketing of molecular diagnostic products. He led GenProbe through its initial public offering on NASDAQ and oversaw its subsequent sale to Chugai Pharmaceutical Co., Ltd. Mr. Bologna has also held seniorlevel positions with Becton Dickinson amp Company and WarnerLambert Company Pfizer , two leading Fortune healthcare companies. Mr. Bologna served as President of the Becton Dickinson Diagnostic Instrument Systems Division and as a Vice President of the WarnerLambert Company.
  • Richard van den Broek / Director
    • Richard van den Broek has served as a member of our Board since December and has served as the Managing Partner of HSMR Advisors, LLC, and investment fund focused on the biotechnology industry since . Mr. van den Broek, previously, was a Partner at Cooper Hill Partners, LLC, an investment fund primarily focused on the healthcare sector for the period of through . Mr. van den Broek serves on the board of directors of Strategic Diagnostic Inc. and is a member of its audit committee. Mr. van den Broek also serves as a director of the board of the directors of Pharmaxis Ltd in Austrailia and Pharmacyclics, Inc. and is a member of the Pharmacyclics audit committee.
  • Kirk K. Calhoun / Director
    • Kirk K. Calhoun has served as a member of our Board since May . Mr. Calhoun joined Ernst amp Young LLP, a public accounting firm, in and served as a partner of the firm from until his retirement in . Mr. Calhoun is a Certified Public Accountant nonpracticing with a background in auditing and accounting. He has served on the boards and audit committees of five public companies in the pharmaceutical industry up until the dates of their respective sales, including Abraxis Bioscience, Inc., Myogen, Inc., Aspreva Pharmaceuticals Compay, Replidyne, Inc., and Adams Respiratory Therapeutics, Inc. Mr. Calhoun received a B.S. in Accounting from the University of Southern California.
  • Sam Chawla / Director
    • Sam Chawla is a nonincumbent nominee to our Board. Mr. Chawla is a Portfolio Manager of Perceptive Advisors LLC, an investment fund focused on the healthcare sector. Mr. Chawla leads Perceptive s Credit Opportunities Fund. Prior to joining Perceptive Advisors in , Mr. Chawla was a Managing Director at UBS Securities LLC in the Global Healthcare Group, where he led origination and execution of financing and advisory assignments for healthcare companies, with a focus on the diagnostics sector. Mr. Chawla s investment banking experience centered on strategic advisory including, M amp A buyside and sellside assignments and financial advisory, including equity and debt capital raises, for both public and private healthcare companies. Prior to joining UBS in September , Mr. Chawla was a Director from January to September and a Vice President from July to January in the Healthcare Investment Banking Group of Credit Suisse LLC, which he original joined as an investment banker in . Mr. Chawla also worked at Bloomberg L.P. and Pelican Life Sciences. Mr. Chawla received an M.B.A. from Georgetown University and a B.A. in Economics from Johns Hopkins University.
  • Kevin R. Harris / Director
    • Mr. Harris previously served as Chief Financial Officer and a director of CyberDefender Corporation from until August and as interim Chief Executive Officer from August until August and as Chief Operating Officer of Statmon Technologies Corp from to . He began his career at KPMG Peat Marwick as a senior auditor. Mr. Harris s other professional experience includes serving as Head of Production, Finance at PolyGram Television, Director of Corporate Financial Planning at MetroGoldwynMayer Studios and Senior Vice President of Finance at RKO Pictures. Mr. Harris earned a Bachelor of Science in Business Administration from California State University, San Bernardino and is a Certified Public Accountant in the State of California.
  • David Schreiber / Director
    • David Schreiber is a nonincumbent nominee to our Board. Mr. Schreiber has held a variety of executive positions in the diagnostic laboratory industry for the past years. For the last years, Mr. Schreiber has and continues to consult for private equity firms to assist with their due diligence efforts and served in various interim operating roles for targeted or existing portfolio companies. From to , Mr. Schreiber was at Quest Diagnostics, initially in a variety of financial roles, his last position being Vice President and General Manager of Quest s Midwest Region, based in Chicago, Illinois. Following Quest, from to , Mr. Schreiber was Senior Vice President and Chief Financial Officer of Dianon Systems, a publicly traded specialized pathology company, until Dianon was acquired by LabCorp. Mr. Schreiber was also a member of Dianon s Board of Directors. Following Dianon, Mr. Schreiber joined the Board of Directors of Specialty Labs, a publicly traded lab company focused on serving the esoteric needs of hospitals. Mr. Schreiber helped lead the turnaround of Specialty Labs which led to its successful sale to Ameripath/Welsh Carson. At the same time, Mr. Schreiber joined and served on the Board of Nanogen, a publicly traded nanotechnology company and also began his consulting career. Mr. Schreiber received a B.S. in Finance and a M.B.A. from Northern Illinois University.
  • Michael Serruya / Director
    • Michael Serruya has served on our Board since March . Since February , Mr. Serruya has been Chairman of Yogen Fruz World Wide Incorporated, a consumer products company and from to February he was President, Chief Executive Officer and Chairman of Yogen Fruz. He is currently on the board of directors of Jamba, Inc. NASDAQ: JMBA , the holding company of Jamba Juice Company, which is a restaurant retailer of food and beverage offerings and owns and franchises Jamba Juice stores. Mr. Serruya was also a member of the Ontario Jobs and Investment Board, an Ontario government organization. Mr. Serruya is currently the president and Chief Executive Officer of CoolBrands International Inc. TSE:COB.A , a company which manufactures and markets frozen novelties, frozen yogurt, ice cream and sorbet products. Mr. Serruya attended Ryerson Polytechnical Institute.
  • David M Wurzer / Director
    • David M. Wurzer joined the Company as a Director in February . Since , Mr. Wurzer has served as Managing Director, Investments, Senior Managing Director, Investments, and beginning April , as Executive Vice President and Chief Investment Officer at Connecticut Innovations CI , the State s venture capital arm. He is responsible for oversight of the CI Venture venture capital portfolio and team, as well as sourcing and analyzing investment opportunities, leading CI investments in entrepreneurial hightech ventures and advising portfolio companies. Prior to joining CI, Mr Wurzer most recently served as Executive Vice President, Treasurer and Chief Financial Officer of CuraGen Corporation, a biopharmaceutical development company, from September through December . He has over years of financial experience with growthoriented companies, including direct involvement with raising capital, strategic transactions and mergers and acquisitions, for both startup companies and publiclyheld entities. Mr. Wurzer serves on the boards of Axerion Therapeutics, Inc., My Gene Counse LLC, Natural Polymer Devices, Inc. and Thetis Pharmaceuticals, LLC, which are privately held, and on the board ofSummit Therapeutics plc NASDAQ: SMMT, LON:SUMM . Mr. Wurzer holds a BBA degree in Accountancy from the University of Notre Dame.

Current Share Structure

  • Market Cap: $29,097 - 03/16/2018
  • Authorized: 70,000,000 - 06/15/2015
  • Issue and Outstanding: 38,795,396 - 06/15/2015
  • Float: 27,341,645 - 06/16/2015

 



Daily Technical Chart for (OTC: RGDXQ)

Daily Technical Chart for (OTC: RGDXQ)


Stay tuned for daily updates and more on (OTC: RGDXQ)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: RGDXQ)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RGDXQ is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of RGDXQ and does not buy, sell, or trade any shares of RGDXQ. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/